Pgiam/iStock via Getty Images bluebird bio ( NASDAQ: BLUE ) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for revenue despite an earnings beat.
After bluebird bio's (.